TAS2R46 IDG GPCR ARCHS4 coexpression (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with TAS2R46 IDG GPCR ARCHS4 coexpression.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with TAS2R46 IDG GPCR ARCHS4 coexpression.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with TAS2R46 IDG GPCR ARCHS4 coexpression.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with TAS2R46 IDG GPCR ARCHS4 coexpression.

Results found

Linked to

 

Label

Description

 

Gene

5-hydroxytryptamine receptor 7 pseudogene 1

Gene

napsin B aspartic peptidase (pseudogene)

Gene

SMG1 pseudogene 3

Gene

SMG1 pseudogene 1

Gene

aspartic peptidase retroviral like 1

Gene

FSHD region gene 1 family member F, pseudogene

Gene

zinc finger protein 781 (pseudogene)

Gene

POU class 5 homeobox 1 pseudogene 4

Gene

BMS1 pseudogene 13

Gene

GRAM domain containing 4 pseudogene 7

  • Gene

    5-hydroxytryptamine receptor 7 pseudogene 1


  • Gene

    napsin B aspartic peptidase (pseudogene)


  • Gene

    SMG1 pseudogene 3


  • Gene

    SMG1 pseudogene 1


  • Gene

    aspartic peptidase retroviral like 1


  • Gene

    FSHD region gene 1 family member F, pseudogene


  • Gene

    zinc finger protein 781 (pseudogene)


  • Gene

    POU class 5 homeobox 1 pseudogene 4


  • Gene

    BMS1 pseudogene 13


  • Gene

    GRAM domain containing 4 pseudogene 7

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.